ImExHS And 2 Australian AI Healthcare Stocks To Watch

Gartner now warns that trillions tied to AI infrastructure could face write downs if revenues fall short, and that kind of reality check is hitting global tech expectations. Australian healthcare AI stocks sit in a different corner of the story. They focus on real world problems like diagnosis and hospital efficiency, where demand is driven by patient outcomes rather than hype. This article highlights three screen picks that show how.

The three stocks below are a starting sample from this theme, and the full screen surfaced 4 more Australian healthcare AI companies with equally compelling narratives that are not covered in the list.

If you want to identify potential leaders, compare fundamentals, and analyze which opportunities best fit your risk tolerance, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener

ImExHS (ASX:IME)

Overview: ImExHS provides cloud-based medical imaging and reporting software, plus teleradiology services, that supply annotated scan data for AI-powered diagnostics.

Operations: The group generates about A$10 million from software and A$21 million from radiology, almost entirely from customers in Latin America.

Market Cap: A$18 million

ImExHS matters for this AI healthcare screen because its AQUILA platform and radiology services sit directly in the data stream that trains diagnostic models. This gives the business a practical, day-to-day role in how hospitals and researchers turn scans into usable AI insight.

"They also understand the challenge now is to drive the software sales and revenue much faster in 2026."

Investor outcomes could look very different depending on how one unseen pressure on future margins and product mix ultimately resolves.

That pressure point is exactly where the story gets interesting, and the full narrative for ImExHS explains how ImExHS could convert its imaging footprint into accelerating software economics and more resilient margins.

Paragon Care (ASX:PGC)

Overview: Paragon Care supplies hospitals and clinics across Australia, New Zealand, and Asia with medical equipment, consumables, and AI-enabled imaging and diagnostic software.

Operations: Paragon Care generates about A$3.5b in ANZ revenue and A$160 million from Asia, with most sales coming from Australia.

Market Cap: A$240 million

Paragon Care brings the AI healthcare theme into everyday clinical practice by distributing imaging hardware that is bundled with AI-driven diagnostic software. This allows hospital buyers to upgrade accuracy and workflow in one purchase rather than stitching solutions together.

"The integration of recent acquisitions and ongoing operational synergies (with a target of $12 million annual run-rate in FY '26), coupled with the consolidation of business functions onto a unified JDE platform, are likely to improve cost efficiencies and structurally enhance net margins and EBITDA."

Investor returns now hinge on whether one quiet shift in product mix tilts more revenue toward those higher-margin AI imaging and software lines.

That quiet shift is exactly what the full narrative for Paragon Care unpacks, showing how Paragon Care could turn efficiency gains into accelerating earnings power and a stronger AI-driven mix.

Artrya (ASX:AYA)

Overview: Artrya develops Salix, a cloud-based AI cardiac imaging platform that helps clinicians detect and assess coronary artery disease from CT scans.

Operations: The business currently records A$0.03 million in revenue from AI-driven coronary CT angiography image analysis technology, all generated in Australia.

Market Cap: A$469.34 million

Artrya plugs directly into the screener theme by using AI to interpret heart imaging, aiming to turn routine chest pain scans into richer, faster decisions for cardiologists.

"Growing adoption of CCTA as a front-line tool for chest pain assessment, together with up to 400,000 scans a year across SAPPHIRE partners at a blended rate of about US$850 per scan across three modules, gives Artrya a clear volume pathway that directly targets future subscription and fee per scan revenue."

Investor outcomes now hinge on how one evolving constraint shapes the balance between long term demand, pricing power and eventual margins.

That tension is exactly what the full narrative for Artrya unpacks, showing how Artrya’s model could convert cardiac scan volume into accelerating economics while keeping risk firmly in view.

Seeking Fresh Alternatives Before They Fly

Fresh opportunities move fast and early momentum can get away from you. Scan these under the radar ideas before the crowd catches up and, while it matters, act now.

• Spot income workhorses that aim to keep paying even when sentiment drops by scanning the 3 dividend fortresses built to highlight consistency and balance sheet strength.
• Chase early price and earnings momentum without only relying on headlines by scanning the curated 4 high quality undervalued stocks that filters for quality and cash generation.
• Position ahead of infrastructure shifts by reviewing the hand picked 43 power grid technology and infrastructure stocks where capital projects, grid upgrades and technology suppliers meet long dated spending plans.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com